Q2 2024 Financial Performance Overview
Affimed N.V. (NASDAQ: AFMD), an innovative leader in immuno-oncology, has recently shared its financial results and strategic developments for the second quarter of 2024. This quarter, the company reported total revenue of €0.2 million, a decrease from €1.4 million in the same quarter last year. This decline is mainly attributed to the conclusion of prior collaborations.
Key Clinical Updates
Throughout the quarter, Affimed made significant progress in its clinical programs, focusing on leveraging the innate immune system to develop groundbreaking therapies. The company provided comprehensive updates on several ongoing studies:
AFM24 with Atezolizumab for NSCLC
A total of 24 patients with EGFR-mutant non-small cell lung cancer (NSCLC) participated in the trial. Out of 17 patients who could be evaluated, the results revealed a complete response (CR) in 1 patient, partial responses (PR) in 3 patients, and 8 patients showed stable disease (SD). This led to an objective response rate of 23.5% and a disease control rate of 70.6%.
Acimtamig (AFM13) Combos for Hodgkin Lymphoma
The combination therapy involving Acimtamig has shown impressive efficacy in patients with relapsed or refractory Hodgkin Lymphoma. Among the 12 enrolled patients, the overall response rate was a remarkable 83.3%, with a complete response rate of 50%. This underscores the potential advantages of this treatment for a challenging patient demographic.
AFM28 Monotherapy in Acute Myeloid Leukemia
The trial assessing AFM28 as a standalone treatment for relapsed or refractory Acute Myeloid Leukemia (AML) yielded promising results, with 3 out of 6 patients achieving either complete response (CR) or complete response with incomplete blood count recovery (CRi). Recruitment for additional patients at the dosage of 300 mg weekly is currently in progress, highlighting the significant advancements in Affimed’s therapeutic pipeline.
Financial Position and Future Outlook
As of June 30, 2024, Affimed's cash, cash equivalents, and short-term investments totaled approximately €34.4 million, providing sufficient support for operations through the latter half of 2025. The company has also managed to reduce its operating expenses to €16.5 million this quarter, primarily due to cuts in research and development costs.
Pipeline Progress and Upcoming Milestones
Affimed is looking forward to several key milestones, with updates on important trials expected at upcoming scientific conferences:
- Results from the LuminICE-203 study are anticipated in Q4 2024.
- Data on overall response rate (ORR) and safety from the EGFR wild-type cohort will also be shared in the same quarter.
- Additional insights from the AFM28-101 study may be presented in future sessions.
Conclusion
Affimed N.V. remains dedicated to advancing cancer treatment through innovative strategies that leverage the innate immune response. With a solid financial foundation and crucial data emerging from ongoing studies, the company's future appears bright.
Frequently Asked Questions
What is Affimed N.V.'s main focus?
Affimed is dedicated to developing immuno-oncology therapies that effectively utilize the innate immune system to fight cancer.
What are the latest results from Affimed's clinical studies?
Recent clinical studies indicate promising response rates for AFM24 in NSCLC and Acimtamig in Hodgkin Lymphoma, showcasing significant advancements in treatment effectiveness.
How is Affimed's financial health?
As of June 30, 2024, Affimed reported €34.4 million in cash and investments, ensuring financial stability through 2025.
What upcoming milestones should investors look for?
Investors can anticipate data updates from key studies in Q4 2024, which aim to further demonstrate the clinical efficacy and safety of Affimed's products.
What innovative therapies is Affimed developing?
Affimed is currently working on several therapies, including AFM24, AFM13, and AFM28, targeting various cancer types based on specific biomarkers.
